Search

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

EHA-AHA Hematology Tutorial On Lymphoid Malignancies Attracts International Audience

EHA-AHA Hematology Tutorial on Lymphoid Malignancies

October 18-20, 2019 | Yerevan, Armenia

Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof Y Hakobyan (Armenian Hematology Association)
Prof S Danielyan (Haematology center after Prof. R. H.

Read more

6th European CAR T-cell Meeting

Dates: February 15-17, 2024
Location: Valencia, Spain
Format: Hybrid
Chairs: Michael Hudecek & Anna Sureda

Registration is closed. Those already registratered can view on-demand content via the platform until March 17.

Read more

Expert opinions for specific hematologic malignancies

Expert opinions for specific hematologic malignancies



Read more

Ukraine Bridge Funding - information for applicants

The EHA Ukraine Bridge Funding Program is a 1-year non-clinical funding opportunity for Ukrainian hematologists and researchers in hematology (see press release here), now in collaboration with the American Society of Hematology, which will participate in funding and the selection…

Read more